Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines.
Aclarubicin (ACLA), which belongs to the antracycline class of antineoplasic agents, has been demonstrated as a differentiating agent for a broad range of human solid tumors and leukemia. By using dihydroethidium as a fluorescent probe, we show the ability of subtoxic (i.e. differentiating) concentration of ACLA to generate reactive oxygen species in both K562 and HL-60 leukemia cell lines. Besides, we have used a calcein-based spectrofluorimetric assay to determine the influence of ACLA treatment on the cellular labile iron pool (LIP). In both cell lines, the LIP level was markedly decreased in the presence of ACLA. Nevertheless, whereas ACLA-induced differentiation was obviously ROS-dependent, the LIP decrease was rather ROS-independent.
Richard
Doriane
D
Unité MéDIAN, CNRS FRE-2141, Faculté de Pharmacie, 51 rue Cognacq-Jay, Reims, France.
Morjani
Hamid
H
Chénais
Benoît
B
D015250:Aclarubicin / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D005456:Fluorescent Dyes; D005609:Free Radicals / Q000378:metabolism*; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D007501:Iron / Q000378:metabolism*; D020014:K562 Cells / Q000187:drug effects; D007938:Leukemia / Q000378:metabolism / Q000473:pathology*; D017382:Reactive Oxygen Species / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D005456:Fluorescent Dyes; D005609:Free Radicals; D017382:Reactive Oxygen Species; D015250:Aclarubicin; D007501:Iron